Prevalencia de fibrilación auricular y factores relacionados en una población del centro de Madrid

Candel, Francisco Javier; Matesanz, M.; Cogolludo, F.; Candel, Ingrid; Mora, C.; Bescos, T.; Martin, Maureen G.; Costa, Isidre Vila I.

doi:10.4321/s0212-71992004001000003

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of non-valvular atrial fibrillation (NVAF) increases with age, affecting 0.5% of the population aged 50–59 and almost 10% of those aged 80–89 [1]. The average age of patients with NVAF is 75, with a greater prevalence seen among women [1-4].…”

Section: Introductionmentioning

confidence: 99%

“…The average age of patients with NVAF is 75, with a greater prevalence seen among women [1-4]. Findings from the long-term cardiovascular study in Framingham, United States (US) and the long-term cohert study in Rotterdam, the Netherlands report a one-in-four lifetime risk of developing Atrial Fibrillation (AF) for those over the age of 40 [2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

Hidalgo

Askari

Vidal

et al. 2014

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundThere is evidence suggesting that most thromboembolic complications could be prevented with adequate pharmacological anticoagulation. We estimated the direct health care costs of anticoagulant treatment with oral vitamin K antagonists in patients diagnosed with non-valvular atrial fibrillation.MethodsThis observational study examined the clinical records of patients diagnosed with non-valvular atrial fibrillation who received anticoagulant treatment with oral vitamin K antagonists. Data from clinical records were used in the study: international normalized ratio, number of monitoring visits, type of anticoagulant, hospital admissions from complications, and concomitant medication. Drug cost was calculated based on the official Spanish Ministry of Health price list. Monitoring expenses were included the cost of the medical supplies used in the procedures. Hospitalization costs were calculated using the Diagnosis Related Group price for each case. Hospital visits costs were calculated by one of four different scenarios, using either the invoice rates for the regional health care authority or cost per visit as established by analytical accounting methods.ResultsWe collected data from 1,257 patients diagnosed with non-valvular atrial fibrillation who were receiving oral anticoagulant therapy. Depending on the scheme used, the direct health care costs for these patients ranged from €423,695 - €1,436,038 per annum. The average cost per patient varied between €392 - €1,341, depending on the approach used. Patients with international normalized ratio values within the therapeutic range on 25% of their visits represented an average cost between €441.70 - €1,592. Those within the therapeutic range on 25%–50% of visits had associated costs of €512.37 - €1,703.91. When international normalized ratio values were within the therapeutic range on 50% - 75% of the visits, the costs ranged between €400.80- €1,375.74. The average cost was €305.23 - €1,049.84 when the values were within the therapeutic range for over 75% of visits.ConclusionsMost direct health care costs associated with the sampled patients arise from the specialist-care monitoring required for the treatment. Good monitoring is inversely related to direct health care costs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

Hidalgo

Askari

Vidal

et al. 2014

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…En España, sin embargo, no hay estudios de ámbito poblacional que hayan analizado la prevalencia de FA en los individuos de más edad y a qué factores se asocia. Los estudios de prevalencia de FA en nuestro medio se han realizado en áreas limitadas [9][10][11] . El estudio CARDIOTENS, el más amplio realizado hasta la fecha 12 , describió una prevalencia global de FA del 4,8% que aumentaba en cada década de la vida (un 1,0% en menores de 50 años, un 11,1% en individuos ≥ 80 años), pero incluyó a pacientes que acudían con cita a las consultas de atención primaria o de cardiología de forma consecutiva, razón por la que no puede considerarse de ámbito poblacional.…”

Section: Introductionunclassified

Prevalencia de fibrilación auricular en la población española de 60 o más años de edad. Estudio PREV-ICTUS

Cea‐Calvo

Redón

Lozano

et al. 2007

Revista Española de Cardiología

118

View full text Add to dashboard Cite

“…Two studies in the Spanish population identified the risk factors frequently associated with AF, which included cardiovascular disease, hypertension, aging, left ventricular hypertrophy, diabetes, ischemic cardiomyopathy, ventricular dysfunction, and widening of the atrial diameter >45 mm 42,43. In this study, hypertension was present in over 50% of patients with AF, heart failure in 14.5%–30%, and diabetes (12%–36.5%), and the prevalence of these comorbidities defines the stroke risk for a significant proportion of these patients as high, as assessed by CHADS 2 or CHADS 2 VASc 2 .…”

Section: Discussionmentioning

confidence: 99%

Burden of disease from atrial fibrillation in adults from seven countries in Latin America

Cubillos¹,

Haddad²,

Kuznik³

et al. 2014

IJGM

View full text Add to dashboard Cite

BackgroundWhile some international studies have published epidemiologic overviews of atrial fibrillation (AF) for the Latin America region, detailed data at the national level are lacking. The aim of this study was to estimate the burden of disease and morbidity associated with AF in adults over 40 years of age in Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Venezuela.MethodsNational health care system databases for each country in the analysis were used to identify cases of AF during 2010 based on ICD-10 codes. Patient comorbidities and treatment patterns in each country were assessed based on available data and extrapolation from relevant published information where local data were incomplete or unavailable. The prevalence of AF in each country was estimated using country-specific, national census data, and assumptions based on a review of the available literature.ResultsPatients in outpatient or hospital care represented over half of the estimated total cases of AF, of whom around 60% were treated as outpatients. Across the seven countries analyzed, 74.5% of AF cases were adults ≥60 years old. However, with increasing age, the proportion of individuals with AF receiving treatment within the national health care systems decreased overall across all seven countries. The most commonly reported comorbidities associated with AF included arterial hypertension (51%–57%), heart failure (14.5%–30%), diabetes (12%–36.5%), and stroke (3%–12.7%).ConclusionThis epidemiologic survey quantifies the scale of the challenge posed by AF to the various national health care systems in Latin America. Overall, ambulatory patients in the national health care systems carry a high risk of developing a stroke, yet a significant proportion of these patients do not receive appropriate anticoagulant therapy.

show abstract

Prevalencia de fibrilación auricular y factores relacionados en una población del centro de Madrid

Cited by 9 publications

References 23 publications

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

Prevalencia de fibrilación auricular en la población española de 60 o más años de edad. Estudio PREV-ICTUS

Burden of disease from atrial fibrillation in adults from seven countries in Latin America

Contact Info

Product

Resources

About